PRESS RELEASES
STENTYS Enrolls First Heart Attack Patient in Pivotal U.S. Clinical Trial
STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
STENTYS to Present Final Results From 1,000 Heart Attack Patient Study at ACC.13
STENTYS clinical study demonstrating superiority of its stents published in American College of Cardiology journal
FDA Approval to Initiate First U.S. Clinical Trial With Self-Apposing® Stent
Interim results on 1 year of APPOSITION III trial
Presentation of the One-Year Interim Results From APPOSITION III Study at TCT Conference
Launch of a New Stent-Delivery System
STENTYS starts clinical trial to broaden portfolio with new drug-eluting stent
APPOSITION III Results
STENTYS expands its product offerings
STENTYS Self-Apposing technology supported by breaking new scientific evidence
Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications
STENTYS concludes clinical trial ahead of plan
Outstanding interim results of STENTYS international clinical study APPOSITION III
STENTYS Self-Apposing Stents in “perfect apposition to vessels” after treating patients with heart attacks
STENTYS completes enrollment of APPOSITION III study
Over 1000 patients have benefited from STENTYS Self-Apposing technology
2011 Half-Year results
Revenues for the 1st half of 2011
Prof. Gilles Montalescot joins STENTYS Scientific Advisory Board
STENTYS recruits Country managers for France and Italy
STENTYS joins Stent for Life Initiative
Stenting in STEMI: Does Size Matter?
STENTYS enrolls first 250 patients within the framework of its Apposition III international study
STENTYS expands operations into four additional European countries
Increased reimbursement of STENTYS drug-eluting stent in Germany
STENTYS begins large-scale, “real life” study with its selfapposing stent for treatment of Heart Attacks
50 patients already enrolled
STENTYS appoints Mr Michel Darnaud to its Board of Directors
APPOSITION II clinical trial results
STENTYS self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction
STENTYS completes enrollment in clinical study of its breakthrough stent to treat Acute Myocardial Infarction.
STENTYS appoints Stanislas Piot as Chief Financial Officer
STENTYS drug-eluting self-expanding stent receives CE Marking.
STENTYS self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS).
STENTYS drug-eluting self-expanding coronary stent shows 4% restenosis in complex lesions.
First patient enrolled in randomized study of STENTYS self-expanding stent vs. conventional stent to treat acute myocardial infarction (AMI).
STENTYS expands Scientific Advisory Board (SAB) on heels of reporting successful clinical trial results for world’s first self-expanding stent to treat AMI.
STENTYS discloses results for world’s first clinical study to treat acute myocardial infarction (AMI) with a self-expanding stent.
LATEST NEWS
